

Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line

Ayene Addisu,¹ Wim Adriaensen,² Arega Balew,³ Mekuria Asfaw,⁴ Ermias Diro,⁵ Amadou Garba Djirmay,⁶ Desalegn Gebree,⁷ Getahun Seid,⁸ Hailemariam Begashaw,⁹ Anthony D Harries,^{10,11} Abera Hirpa Adugna,⁷ Zeleke Ayalew Jejaw,¹ Edward Mberu Kamau,¹² Tigist Kelbo,⁴ Marcel Manzi,¹³ Dana Medebo Daniel,¹⁴ Ashok Moloo,⁶ Piero Olliaro,¹² Philip Owiti,¹⁵ John C Reeder,¹² Mbazi Senkoro,¹⁶ Kuda Takarinda,¹⁷ Robert Terry,¹⁸ Collins Timire,¹⁷ Samson Tucho,¹⁹ Hannock Tweya,^{10,20} Yeshanehe Wendemagegn,²¹ Kristien Verdonck,² Florian Vogt,² Saskia van Henten,² Johan van Griensven,²² Bekele Worku,²³ Maria Zolfo,² Rony Zachariah,¹² Ethiopia SORT IT Neglected Tropical Diseases Group

"We must become bigger than we have been: more courageous, greater in spirit, larger in outlook."

Emperor Haile Selassie

To cite: Addisu A, Adriaensen W, Balew A, *et al.* Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line. *BMJ Glob Health* 2019;**4**:e001334. doi:10.1136/bmjgh-2018-001334

Handling editor Seye Abimbola

Received 4 December 2018
Revised 9 January 2019
Accepted 12 January 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Rony Zachariah;
zachariah1@who.int

It was in the city of Gondar in Ethiopia, one of the highest burden countries for neglected tropical diseases (NTDs)¹ and currently home to 16 to 20 recognised NTDs (table 1), that a unanimous desire was expressed by scientists, policy makers and health workers from around the world (the forum was an operational research training on NTDs organised by the Structured Operational Research and Training Initiative (SORT IT). SORT IT is a global partnership coordinated by the Special Programme for Research and Training in Tropical Diseases (TDR) hosted at the WHO. <http://www.who.int/tdr/capacity/strengthening/sort/en>), for urgent reflection on how to garner support and hasten the pace towards achieving the fast approaching Sustainable Development Goal (SDG) target of eliminating NTDs by 2030.² Concerns, raised by the group are articulated below:

First, there is the term 'Neglected Tropical Diseases', coined by Peter Hotez and colleagues in 2003 with the noble intention of propelling political momentum, catalysing donor funding and making quantum shifts in research and development (R&D).³ The question today is whether designating a specific group of diseases as being 'neglected' does not carry with it a negative and disempowering connotation. Populations affected

Summary box

- ▶ The international community has pledged through the Sustainable Development Goals to eliminate neglected tropical diseases by 2030.
- ▶ Authors from 19 institutions around the world call for urgent reflection and a change in mind-set to garner support and hasten progress towards achieving this fast approaching target.
- ▶ They advocate for an empowering approach that will propel political momentum, milestones and targets for accountability, new science in drug development and increased funding particularly from G20 countries.

by NTDs already face neglect by being the world's poorest and facing social stigmatisation, prejudice and marginalisation. Lacking a 'strong political voice', these communities have a low profile and status in public health priorities.⁴ Having the label of 'neglected' added to their illnesses may accentuate their predicament. Put simply, how can human beings, who risk being diminished by being designated as 'neglected' by us in the health system, be considered equal partners in their own care? Language is more than words: it has the power to transform the way people think and behave.⁵

This term may thus allow politicians and donors to maintain a 'business-as-usual' mode by accepting the idea of neglect as an unchangeable paradigm, dampening the drivers behind political impetus and funding. The quote from a SORT IT

Table 1 The 20 neglected tropical diseases recognised by the WHO*

Category	Disease
Protozoan infections	1. Chagas disease 2. Human African trypanosomiasis 3. Leishmaniasis
Helminth infections	4. <i>Taenia solium</i> (neuro) cysticercosis/ Taeniosis 5. Dracunculiasis 6. Echinococcus 7. Foodborne trematodiasis 8. Lymphatic filariasis 9. Onchocerciasis 10. Schistosomiasis 11. Soil-transmitted helminthiasis (ascariasis, Hookworm diseases, trichuriasis, strongyloidiasis)
Bacterial infections	12. Buruli ulcer 13. Leprosy 14. Trachoma 15. Yaws
Viral infections	16. Dengue and chikungunya fevers 17. Rabies
Fungal Infections	18. Mycetoma, chromoblastomycosis, deep mycosis
Ectoparasitic infections	19. Scabies, Myiasis
Venom	20. Snakebite envenoming

*Source. World Health Organisation. Neglected Tropical Diseases 2017 https://www.who.int/neglected_diseases/diseases/en/.

participant was illustrative *'I hoped to do my PhD on intestinal worms, but I was quickly dissuaded by many in academic and government circles saying it is a neglected disease'*.

The Amharic (Ethiopian) translation of NTDs reads 'Tropical diseases needing special attention'-an empowering designation with an imperative for action which reflects the mind-set change that is urgently needed.

Second, the 15 years of naming this constellation of diseases of poverty as 'Neglected Tropical Diseases' have not really changed the paradigm, as we have only kept adding to the list of NTDs with none coming off permanently.^{6 7} This is proof that much more is needed to eliminate NTDs, including clear objective criteria for getting on or off the list. Furthermore, since being removed from the NTD list may be a disincentive for continued funding support it may encourage passiveness.

Bringing NTDs into the SDG agenda is laudable, but strong activism and political momentum is now urgently needed.⁸ HIV/AIDS is a good example. The '3 by 5' initiative, launched by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and WHO in 2003, was a global target to provide life-prolonging antiretroviral treatment (ART) to three million people living with HIV/AIDS in low-income and middle-income countries by the end of 2005.⁹ This was followed

by Universal Access targets, the Treatment 2.0 Strategy and the UNAIDS 90-90-90 treatment targets. All of these were important drivers that simplified therapy, increased treatment coverage and crystallised the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.¹⁰ From hundreds on ART in 2003, the result was 21.7 million on ART by 2017.¹¹ Such initiatives reached fruition because of a public health approach to ART scale-up as part of Universal Health Coverage (UHC). It is time to gear similar political and funding impetus towards NTDs. Since the NTD package includes a diversity of diseases, the role of disaggregated or appropriately combined treatment targets may help.

Third, the list of NTDs is diverse, with parasitic, bacterial, viral, fungal infections and snakebite envenoming.³ Unlike diseases such as HIV/AIDS, TB and Malaria, there are practical difficulties in building strong communities of practice, as NTD work is often confined to silos of specific diseases.⁴ While recognising the specificities of each condition, new ways of building an integrated approach that compels stake holders to look beyond 'the trees to see the forest' are needed.

The WHO Roadmap strategy on control, elimination and eradication of NTDs is commendable, but it is geared only until 2020 and urgent work is needed to align it with the 2030 SDG target.^{8 11} Importantly, the road map is largely focused on the diseases for which medicines and large-scale prevention and treatment options exist, such as for onchocerciasis, lymphatic filariasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma.¹² Implementation of large-scale prevention and treatment is often hampered by shortages of drugs and vaccines which needs to be addressed. Vector control activities are also required for vectorborne diseases, such as dengue and leishmaniasis, while veterinary public health as part of the 'One Health' approach is needed for zoonotic diseases, such as taeniasis/neuro-cysticercosis, echinococcosis and rabies. The provision of safe water, sanitation and hygiene (WASH) is another key component of the WHO strategy to overcome NTDs such as trachoma and STH. These interventions, and how they are integrated into broader health systems and within the principles of UHC, are spelt out in the WHO's 4th comprehensive Report on NTDs, but in contrast to tuberculosis and HIV/AIDS, this lacks clear and measurable targets and milestones by which to judge progress.¹³ If we are to eliminate NTDs by 2030 the 'how to' of this gigantic task needs to be defined including milestones and targets.

Finally, there is an urgent need for a quantum shift in funding for R&D and for treatment access. Despite evidence that interventions to address NTDs are one of the best health investments, only 0.6% of development assistance for health is allocated to NTDs that affect about 1.5 billion people or roughly 20% of the




Figure 1 Impact of market on product pipeline (diagnostics, drugs vaccines) starting from the preclinical stage for various diseases.¹⁵ Type II diseases: are incident in both rich and poor countries with substantial proportion of the cases in poor countries.¹⁵ Type III disease: are those that are overwhelmingly or exclusively incident in developing countries.¹⁵ NTDs, neglected tropical diseases.

world population.¹⁴ This is clear evidence of inequity in global health financing which needs correction.¹⁴ In 2015, WHO estimated that US\$18 billion (US\$3.6 billion a year) was the investment target to achieve the NTD road map until 2020. The reality lies at less than US\$ 200 million a year - a 94% yearly shortfall.^{8 11}

Similarly, there is an inverse relationship between commercial market size and products in the R&D pipeline. NTDs lie towards the bottom of the pile (figure 1).¹⁵ A 2018 TDR publication drew attention to the fact that the current R&D pipeline is dominated by three diseases—malaria, HIV/AIDS and tuberculosis. For NTDs, 12 (57%) of 20 NTDs have nothing at all in the pipeline (figure 2).¹⁶ This finding reiterates the need to establish a new funding model for NTD-related R&D and the need for national and regional investments. Africa is the continent most affected by the NTD burden, but contributes less than 1% to global expenditure on R&D.¹⁷ The BRICS (Brazil, Russia, India, China and South Africa) and G20 countries have an opportunity to show leadership in addressing this challenge. A possible way forward is to call on G20 countries to generate a special fund for NTDs since the NTD burden is highest among the poor in G20 countries (together with Nigeria) and they have capacity to develop generic

products. Furthermore, NTDs are pervasive wherever poverty and vulnerable populations exist, including emerging market economies.¹⁸ If these countries would effectively implement NTD programmes, a large proportion of the NTD burden would be resolved.^{7 18} NTD endemic populations are the least likely to be able to meet SDG targets that include UHC (target 3.8), safe water (target 6.1) and sanitation (target 6.2) and as such they can serve as tracers of equity in progress towards the SDGs.

Reflection on how existing global funding mechanisms such as the Global Fund Against AIDS, TB and Malaria (GFATM) could also embrace NTDs as part of their portfolio is needed more than ever before. From an operational perspective, this seems logical as areas endemic for NTDs also tend to be endemic for HIV/AIDS, tuberculosis and malaria. Coinfections with STH and schistosomiasis are also known to exacerbate the progression of the aforementioned diseases.¹⁹ A promising way of pushing the NTD agenda and leveraging political attention and resources would thus be an integrated management approach to NTDs, Malaria, Tuberculosis and HIV and a call for public health action at a broad level in countries. Such an approach would also strengthen the general health




Figure 2 Number of candidate products (diagnostics, drugs vaccines) for neglected diseases, by disease condition in 2017.

system with benefits to the management and control of NTDs.

When new drugs are developed for NTDs, they need to be deployed at programmatic level as quickly as possible, and here the funding support from GFATM for operational research would facilitate a win-win situation. Whatever the eventual choice may be, articulating the mechanisms for funding remains a glaring gap.

In conclusion, in countries like Ethiopia how well we do with NTDs could serve as ‘tracers of equity’ towards the SDGs and markers of the philosophy of ‘leaving none behind’. We must succeed, but that will depend on the backing of a supportive political environment, coupled with new science, funding (particularly by G20 countries) and robust advocacy. Most of all, we will need a greatly strengthened sense of global solidarity focused on the needs of the poorest and most vulnerable and with the participation of all countries, all stakeholders and all people.⁴ If we are to transform the NTD world for the SDGs, it will require us to first transform our thinking and actions.

Author affiliations

- ¹Medical parasitology and internal medicine, University of Gondar, Gondar, Ethiopia
- ²Tropical Diseases, Institute of Tropical Medicine, Antwerp, Belgium
- ³Internal medicine, Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia
- ⁴Research and training, Arba Minch University, Arba Minch, Ethiopia
- ⁵Internal Medicine, University of Gondar, Gondar, Ethiopia
- ⁶Neglected Tropical Diseases, World Health Organisation, Geneva, Switzerland
- ⁷Malaria, neglected tropical and zoonotic diseases, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- ⁸Boru Meda Hospital, Amhara Regional Health Bureau, Amhara, Ethiopia
- ⁹Health programme, The Jimmy Carter Center, Addis Abeba, Ethiopia

- ¹⁰Center for Operational Research, International Union Against TB and Lung Disease, Paris, France
- ¹¹Tropical medicine, London School of Hygiene and Tropical Medicine, London, UK
- ¹²Research for implementation, Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
- ¹³Operational research (LUXOR), Médecins Sans Frontières (LuxOR), Luxembourg City, Luxembourg
- ¹⁴Institute of health, Jimma University, Jimma, Ethiopia
- ¹⁵Center for operational research, International Union Against TB and Lung Disease, Nairobi, Kenya
- ¹⁶Medical research, National Institute for Medical Research, Dar es Salaam, Tanzania
- ¹⁷Center for operational research, International Union Against TB and Lung Disease, Harare, Zimbabwe
- ¹⁸Research Policy, Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
- ¹⁹Clinical monitoring, KalaCORE Program, Amigos Da Silva, Addis Abeba, Ethiopia
- ²⁰Monitoring and evaluation, Light House Trust, Paris, France
- ²¹Dermatology and Veneriology, Bahar Dar University, Bahir Dar, Ethiopia
- ²²Clinical Sciences, Instituut voor Tropische Geneeskunde, Antwerpen, Belgium
- ²³Malaria and neglected tropical diseases, World Health Organisation Country Office, Addis Abeba, Ethiopia

Contributors RZ wrote the first draft of the manuscript which was reviewed by all authors who significantly contributed to the content and approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Disclaimer The views expressed in this article are those of the authors and may not necessarily reflect those of their affiliated institutions.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data from this article have already been published and available in the public domain.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Deribe K, Meribo K, Gebre T, *et al*. The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. *Parasit Vectors* 2012;5.
2. Nations U. Transforming our world: the 2030 agenda for sustainable development. Available: <http://sustainabledevelopment.un.org/post2015/transformingourworld> [Accessed 18 Sep 2018].
3. Winkler AS, Klohe K, Schmidt V, *et al*. Neglected tropical diseases – the present and the future. *Tidsskriftet* 2018;138.
4. WHO. Why are some tropical diseases called "neglected"? Available: <https://www.who.int/features/qa/58/en/> [Accessed 12 Oct 2018].
5. Zachariah R, Harries AD, Srinath S, *et al*. Language in tuberculosis services: can we change to patient-centred terminology and stop the paradigm of blaming the patients? *Int J Tuberc Lung Dis* 2012;16:714–7.
6. The Lancet. Snake-bite envenoming: a priority neglected tropical disease. *The Lancet* 2017;390.
7. Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. *The Lancet* 2017;389:312–25.
8. Smith J, Taylor EM. What is next for NTDs in the era of the sustainable development goals? *PLoS Negl Trop Dis* 2016;10:e0004719.
9. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. *Curr Opin HIV AIDS* 2013;8:12–18.
10. UNAIDS. UNAIDS data 2017. Available: http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf [Accessed 11 Oct 2018].
11. WHO. *Investing to overcome the global impact of neglected tropical diseases. WHO third report on neglected tropical diseases*. Geneva: WHO, 2015.
12. WHO. A roadmap for implementation. accelerating work to overcome the global impact of neglected tropical diseases. Available: http://www.who.int/neglected_diseases/resources/WHO_HTM_NTD_2012.1/en/ [Accessed 11 Oct 2018].
13. WHO. Fourth who report on neglected tropical diseases. Available: <http://apps.who.int/iris/bitstream/handle/10665/255011/9789241565448-eng.pdf;jsessionid=C7B9BC21ADCD40A5937D6849C6059C8F?sequence=1> [Accessed 14 Oct 2018].
14. Liese BH, Houghton N, Teplitskaya L. Development assistance for neglected tropical diseases: progress since 2009. *Int Health* 2014;6:162–71.
15. TDR. Health product research and development fund: a proposal for financing and operation available. Available: http://www.who.int/tdr/publications/r_d_report/en/ [Accessed 11 Oct 2018].
16. Young R, Bekele T, Gunn A, *et al*. Developing new health technologies for neglected diseases: a pipeline Portfolio review and cost model. *Gates Open Res* 2018;2.
17. Fonn S, Ayiro LP, Cotton P, *et al*. Repositioning Africa in global knowledge production. *The Lancet* 2018;392:1163–6.
18. Hotez PJ. Blue marble health Redux: neglected tropical diseases and Human development in the group of 20 (G20) Nations and Nigeria. *PLoS Negl Trop Dis* 2015;9:e0003672.
19. Ndeffo Mbah ML, Kjetland EF, Atkins KE, *et al*. Cost-effectiveness of a community-based intervention for reducing the transmission of *Schistosoma haematobium* and HIV in Africa. *Proceedings of the National Academy of Sciences* 2013;110:7952–7.